Rallybio (NASDAQ:RLYB) Announces Quarterly Earnings Results, Misses Estimates By $0.26 EPS

Rallybio (NASDAQ:RLYB) posted its earnings results on Wednesday. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.26), FiscalAI reports. Rallybio had a negative net margin of 911.07% and a negative return on equity of 54.44%. The company had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.21 million.

Rallybio Price Performance

Shares of Rallybio stock traded down $0.09 during trading on Friday, hitting $14.12. The stock had a trading volume of 24,596 shares, compared to its average volume of 233,515. The firm’s fifty day simple moving average is $9.77 and its 200-day simple moving average is $6.99. The stock has a market cap of $74.69 million, a PE ratio of -5.52 and a beta of -1.10. Rallybio has a 12 month low of $2.16 and a 12 month high of $15.31.

Insider Activity

In other news, major shareholder Adar1 Capital Management, Llc bought 50,000 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $700,000.00. Following the acquisition, the insider owned 829,784 shares of the company’s stock, valued at $11,616,976. The trade was a 6.41% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders have bought 206,705 shares of company stock valued at $2,890,110. 10.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Rallybio

Institutional investors have recently made changes to their positions in the company. XTX Topco Ltd lifted its holdings in shares of Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after acquiring an additional 38,205 shares during the last quarter. Susquehanna International Group LLP lifted its holdings in shares of Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after acquiring an additional 113,031 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after acquiring an additional 2,996 shares during the last quarter. Citadel Advisors LLC lifted its holdings in shares of Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after acquiring an additional 373,821 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after acquiring an additional 120,892 shares during the last quarter. Institutional investors own 90.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on RLYB shares. Wall Street Zen upgraded shares of Rallybio to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rallybio in a research report on Friday, May 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.